Shots:
- The Chinese NMPA has accepted NDA & granted priority review to fanregratinib (HMPL-453) for the treatment of adults with advanced, metastatic, or unresectable ICC with FGFR 2 fusion/rearrangement who have previously received systemic therapy
- NDA was supported by the P-II trial in China, which met its 1EP of improved ORR, with 2EPs findings, incl. PFS, DCR, DoR & OS are also supporting the 1EP results; data to be presented in the future
- Fanregratinib (PO) inhibits FGFR 1, 2 & 3 to prevent tumor growth, angiogenesis promotion & anti-tumor resistance
Ref: Globenewswire | Image: HUTCHMED | Press Release
Related News: HUTCHMED Completes Enrollment in Global P-III (SAFFRON) Study of Orpathys + Tagrisso in Lung Cancer Patients
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
